ReviewImmunological reviews2011
Human asthma phenotypes: from the clinic, to cytokines, and back again.
Review in Immunological reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 185 citations in OpenAlex.
- Stability of Type 2 Inflammation in a 12-Year Adult-Onset Asthma Follow-Up Study.Journal of asthma and allergy · 2026Article
- ILC2 Diversity, Location, and Function in Pulmonary Disease.Immunological reviews · 2025Review
- Article
- ANO1: central role and clinical significance in non-neoplastic and neoplastic diseases.Frontiers in immunology · 2025Review
- Immunological factors, important players in the development of asthma.BMC immunology · 2024Review
- Biomarker-guided withdrawal of inhaled corticosteroids in asthma patients with a non-T2 inflammatory phenotype - a randomized controlled trial study protocol.BMC pulmonary medicine · 2023Article
- Severe Asthmatic Responses: The Impact of TSLP.International journal of molecular sciences · 2023Review
- Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice.International journal of molecular sciences · 2023Review
- Precision Medicine in Asthma Therapy.Handbook of experimental pharmacology · 2023Article
- Assessment of Fraction of Exhaled Nitric Oxide and Soluble Receptor for Advanced Glycation End Products Biomarkers for Jordanian Asthmatic Children.Journal of asthma and allergy · 2023Article
- How does cigarette smoking affect airway remodeling in asthmatics?Tobacco induced diseases · 2023Review
- Novel potential treatable traits in asthma: Where is the research taking us?The journal of allergy and clinical immunology. Global · 2022Review
- Phenotyping in acute respiratory distress syndrome: state of the art and clinical implications.Current opinion in critical care · 2022Review
- Different Phenotypes in Asthma: Clinical Findings and Experimental Animal Models.Clinical reviews in allergy & immunology · 2022Review
- Purified Native and Recombinant MajorJournal of fungi (Basel, Switzerland) · 2021Article
- Predicting Treatment Outcomes Using Explainable Machine Learning in Children with Asthma.Children (Basel, Switzerland) · 2021Article
- Epithelial miR-141 regulates IL-13-induced airway mucus production.JCI insight · 2021Article
- Asthma Phenotypes as a Guide for Current and Future Biologic Therapies.Clinical reviews in allergy & immunology · 2020Review
- Blood and Salivary Amphiregulin Levels as Biomarkers for Asthma.Frontiers in medicine · 2020Article
- Association Between FeNO, Total Blood IgE, Peripheral Blood Eosinophil and Inflammatory Cytokines in Partly Controlled Asthma.Journal of asthma and allergy · 2020Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A large body of experimental evidence supports the hypothesis that T-helper 2 (Th2) cytokines orchestrate allergic airway inflammation in animal models. However, human asthma is heterogeneous with respect to clinical features, cellular sources of inflammation, and response to common therapies. This disease heterogeneity has been investigated using sputum cytology as well as unbiased clustering approaches using cellular and clinical data. Important differences in cytokine-driven inflammation may underlie this heterogeneity, and studies in human subjects with asthma have begun to elucidate these molecular differences. This molecular heterogeneity may be assessed by existing biomarkers (induced sputum evaluation or exhaled nitric oxide testing) or may require novel biomarkers. Effective testing and application of emerging therapies that target Th2 cytokines will depend on accurate and easily obtained biomarkers of this molecular heterogeneity in asthma. Furthermore, whether other non-Th2 cytokine pathways underlie airway inflammation in specific subsets of patients with asthma is an unresolved question and an important goal of future research using both mouse models and human studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.